Literature DB >> 18622042

A search for colocalization of serotonin 5-HT2A and 5-HT1A receptors in the rat medial prefrontal and entorhinal cortices--immunohistochemical studies.

K Wedzony1, A Chocyk, M Maćkowiak.   

Abstract

Recently developed antipsychotic drugs ameliorating the negative symptoms of schizophrenia act not only on dopamine D2 receptors but also on serotonin 2A (5-HT2A) and 1A (5-HT1A) receptors in specific regions of the cerebral cortex. Since it is not yet known whether serotonin 5-HT1A and 5-HT2A receptors coexist in the same population of neurons in the cortex, the present study investigated their colocalization in the rat medial prefrontal (MPC) and entorhinal (EC) cortices. Using antibodies that recognize epitopes specific to the serotonin 5-HT2A or 5-HT1A receptors, studies employing confocal microscopy have shown that in the MPC 5-HT2A receptors are preferentially, if not exclusively, present on the pyramidal neurons and that 5-HT1A-immunopositive material is present in the axonal hillocks and, to lower extend, in cytoplasm of presumably pyramidal cell bodies. With the regard of labeling of active receptors (i.e. present in shafts and axonal hillocks) we found that about 38% of neurons positive for the presence of serotonin 5-HT2A receptors, are also positive for serotonin 5-HT1A receptors in the MPC. In the EC, only 22% of serotonin 5-HT2A-positive neurons were positive for serotonin 5-HT1A receptor-immunoreactivity. In the respect of cytoplasmatic serotonin 5-HT1A receptor-immunoreactivity (possibly inactive receptors), 65% and 73% of serotonin 5-HT2A receptor-positive neurons were colocalized with serotonin 5-HT1A receptors in the MPC and EC, respectively. Data obtained on serotonin 5-HT2A and 5-HT1A receptor localization provide anatomical grounds for at least three distinct populations of pyramidal neurons, one governed only by 5-HT2A, one only by 5-HT1A and one by both types of serotonin receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622042

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  7 in total

1.  Neuron density and serotonin receptor binding in prefrontal cortex in suicide.

Authors:  Mark D Underwood; Suham A Kassir; Mihran J Bakalian; Hanga Galfalvy; J John Mann; Victoria Arango
Journal:  Int J Neuropsychopharmacol       Date:  2011-05-09       Impact factor: 5.176

Review 2.  A comparison of the subsecond dynamics of neurotransmission of dopamine and serotonin.

Authors:  Katie A Jennings
Journal:  ACS Chem Neurosci       Date:  2013-04-29       Impact factor: 4.418

Review 3.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

4.  Repeated Clozapine Increases the Level of Serotonin 5-HT1AR Heterodimerization with 5-HT2A or Dopamine D2 Receptors in the Mouse Cortex.

Authors:  Marta Szlachta; Maciej Kuśmider; Paulina Pabian; Joanna Solich; Magdalena Kolasa; Dariusz Żurawek; Marta Dziedzicka-Wasylewska; Agata Faron-Górecka
Journal:  Front Mol Neurosci       Date:  2018-02-15       Impact factor: 5.639

5.  The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.

Authors:  Joanna M Wierońska; Francine C Acher; Anna Sławińska; Piotr Gruca; Magdalena Lasoń-Tyburkiewicz; Mariusz Papp; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2013-03-10       Impact factor: 4.530

6.  Comodulation of dopamine and serotonin on prefrontal cortical rhythms: a theoretical study.

Authors:  Da-Hui Wang; Kongfatt Wong-Lin
Journal:  Front Integr Neurosci       Date:  2013-08-05

7.  Activity-dependent serotonergic excitation of callosal projection neurons in the mouse prefrontal cortex.

Authors:  Emily K Stephens; Daniel Avesar; Allan T Gulledge
Journal:  Front Neural Circuits       Date:  2014-08-26       Impact factor: 3.492

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.